Company intelligence / Profile preview

Shanghai Jianhua Fine Biological Products

Ownership: Private
Development stage: Other

Overview

Shanghai Jianhua Fine Biological Products, as part of a larger group, develops and markets innovative biologicals such as recombinant human epidermal growth factor ("Healin") for wound care, as well as a portfolio of hyaluronic acid-based dermal fillers ("Matrifill," "Janlane," etc.) that are approved and commercially available in China. The company has completed clinical trials for several generations of its HA filler products, with ongoing R&D into new formulations to maintain market leadership in the non-invasive medical aesthetics sector[6].

Therapeutic areas: Dermatology
Modalities: BiologicRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Jianhua Fine Biological Products.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Jianhua Fine Biological Products.

Explore the full profile